Febrile neutropenia (FN) is common among hematologic malignancy patients, including recipients of hematopoietic cell transplantation (HCT) and cellular therapies such as chimeric antigen receptor (CAR)-T-cell therapy. Prompt empiric antibiotic use has been the mainstay for decades but a “one-size-fits-all” approach is no longer broadly accepted, as treatment-related infectious risk are more understood. Growing antimicrobial resistance is an increasing clinical challenge. Evolving strategies on de-escalation of broad-spectrum antibiotics in FN without identified infection are areas of particular interest.
CITATION STYLE
Stohs, E. J., Abbas, A., & Freifeld, A. (2024, April 1). Approach to febrile neutropenia in patients undergoing treatments for hematologic malignancies. Transplant Infectious Disease. John Wiley and Sons Inc. https://doi.org/10.1111/tid.14236
Mendeley helps you to discover research relevant for your work.